NUCB2, nucleobindin 2, 4925

N. diseases: 140; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028756
Disease: Obesity, Morbid
Obesity, Morbid 		0.010 GeneticVariation disease BEFREE Identification of mutations in the NUCB2/nesfatin gene in children with severe obesity. 23141462 2012
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.340 AlteredExpression disease BEFREE Our results indicated that the high expression of NUCB2 in PCa was associated with lymph node metastasis, preoperative PSA, Gleason score, and angiolymphatic invasion. 23958433 2013
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.300 AlteredExpression disease BEFREE Increased nucleobindin-2 (NUCB2) transcriptional activity links the regulation of insulin sensitivity in Type 2 diabetes mellitus. 23765387 2013
CUI: C0028754
Disease: Obesity
Obesity 		0.300 AlteredExpression disease BEFREE Potential implications in human obesity will be discussed in relation to the evidence of changes in circulating levels of NUCB2/nesfatin-1 in disease states, the occurrence of genetic NUCB2 polymorphisms and--in contrast to several other hormones--the independence of leptin signalling known to be blunted under conditions of chronically increased body weight. 23980879 2013
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.060 AlteredExpression disease BEFREE Nucleobindin 2 (NUCB2) abnormal expression has been reported in gastric cancer and breast cancer. 23958433 2013
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X 		0.060 Biomarker disease BEFREE As a result, nesfatin-1 may be a novel target for exploring the underlying mechanisms and the treatment of metabolic syndromes. 23955480 2013
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X 		0.060 Biomarker disease BEFREE Histidine supplementation could improve IR, reduce BMI, fat mass and NEFA and suppress inflammation and oxidative stress in obese women with MetS; histidine could improve IR through suppressed pro-inflammatory cytokine expression, possibly by the NF-κB pathway, in adipocytes. 23361591 2013
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.060 AlteredExpression disease BEFREE Nucleobindin 2 (NUCB2) abnormal expression has been reported in gastric cancer and breast cancer. 23958433 2013
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.060 AlteredExpression phenotype BEFREE Our results indicated that the high expression of NUCB2 in PCa was associated with lymph node metastasis, preoperative PSA, Gleason score, and angiolymphatic invasion. 23958433 2013
CUI: C0003123
Disease: Anorexia
Anorexia 		0.050 Biomarker disease BEFREE Nucleobindin 2 (NUCB2) is a precursor of nesfatin-1, a hypothalamic anorectic neuropeptide. 23266808 2013
CUI: C0003123
Disease: Anorexia
Anorexia 		0.050 Biomarker disease BEFREE Two recently described peptide hormones, neuronostatin and nesfatin-1, both act in the brain to induce anorexia, albeit through potentially different mechanisms. 23601419 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.040 AlteredExpression disease BEFREE Our results indicated that the high expression of NUCB2 in PCa was associated with lymph node metastasis, preoperative PSA, Gleason score, and angiolymphatic invasion. 23958433 2013
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.040 AlteredExpression disease BEFREE Our results indicated that the high expression of NUCB2 in PCa was associated with lymph node metastasis, preoperative PSA, Gleason score, and angiolymphatic invasion. 23958433 2013
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.030 Biomarker group BEFREE Among appetite regulatory peptides, alteration of expressions of leptin and ghrelin is demonstrated in cachectic cancer patients, but nesfatin-1 has not been yet studied in cancer. 23269222 2013
CUI: C0020175
Disease: Hunger
Hunger 		0.030 Biomarker phenotype BEFREE The recently discovered nesfatin-1 is regulated by hunger and satiety. 23526235 2013
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 Biomarker group BEFREE Among appetite regulatory peptides, alteration of expressions of leptin and ghrelin is demonstrated in cachectic cancer patients, but nesfatin-1 has not been yet studied in cancer. 23269222 2013
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.010 AlteredExpression disease BEFREE Serum nesfatin-1 levels were lower in lung cancer patients than in healthy subjects (0.52±0.19ng/ml vs 0.75±0.23ng/ml; p<0.001). 23269222 2013
CUI: C0271650
Disease: Impaired glucose tolerance
Impaired glucose tolerance 		0.010 AlteredExpression phenotype BEFREE Plasma NUCB2-1 levels were elevated in subjects with both nT2DM and IGT compared with normal controls. 23765387 2013
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.010 AlteredExpression disease BEFREE Serum nesfatin-1 levels were lower in lung cancer patients than in healthy subjects (0.52±0.19ng/ml vs 0.75±0.23ng/ml; p<0.001). 23269222 2013
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.010 AlteredExpression disease BEFREE Serum nesfatin-1 levels were lower in lung cancer patients than in healthy subjects (0.52±0.19ng/ml vs 0.75±0.23ng/ml; p<0.001). 23269222 2013
CUI: C4524268
Disease: Advanced lung cancer
Advanced lung cancer 		0.010 AlteredExpression disease BEFREE We investigated serum nesfatin-1 level in advanced lung cancer patients. 23269222 2013
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.340 AlteredExpression disease BEFREE In conclusion, we demonstrated that high NUCB2 mRNA expression correlated with poor overall survival in patients with PCa. 24092574 2014
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.060 Biomarker disease BEFREE Nucleobindin 2 (NUCB2) has been demonstrated to play critical roles in tumorigenesis and tumor development of breast cancer. 24092574 2014
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.060 Biomarker disease BEFREE Nucleobindin 2 (NUCB2) has been demonstrated to play critical roles in tumorigenesis and tumor development of breast cancer. 24092574 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.050 Biomarker group BEFREE Nucleobindin 2 (NUCB2) has been demonstrated to play critical roles in tumorigenesis and tumor development of breast cancer. 24092574 2014